Advances in Clinical Management Strategies for Sarcopenia: From Exercise and Nutrition to Pharmacotherapy and Comprehensive Interventions.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing evidence across interventions without systematic search protocol or quantitative pooling
PubMed 42348067 · doi:10.1007/s12035-026-06017-1
What was done
This review synthesizes clinical management strategies for sarcopenia across exercise modalities, nutritional interventions, emerging pharmacotherapies, and comprehensive multi-domain management. Interventions evaluated include resistance, multicomponent, and blood flow restriction training, nutritional strategies focusing on protein intake (1.2–1.5 g/kg daily), essential amino acids, β-hydroxy-β-methylbutyrate, and vitamin D, as well as investigational pharmacotherapies targeting myostatin/activin, androgen, metabolic, and inflammatory pathways.
What was found
The abstract reports qualitative narrative findings rather than specific quantitative effect sizes or aggregate numbers. It highlights that exercise and targeted nutrition improve muscle mass and function. Investigational pharmacotherapies (such as Bimagrumab and LPCN 1148) increase muscle mass in clinical trials, but none are globally approved, and functional benefits alongside long-term safety remain unestablished.
Why it matters
This review outlines the current evidence landscape for sarcopenia management, emphasizing validated lifestyle approaches while delineating the limitations of emerging drug candidates.
Limits
As a narrative review, it does not provide systematic search methods, pooled quantitative effect estimates, or study-level quality grading. The underlying literature is constrained by diagnostic heterogeneity, uncertain functional translation of pharmacological gains, and poor long-term intervention adherence.